Acne scarring significantly affects physical appearance and psychological well-being, prompting the exploration of various treatment options, including ablative and non-ablative laser therapies. The debate around their efficacy and safety persists, underscoring the need for a comprehensive analysis. This meta-analysis compares the therapeutic outcomes and safety profiles of ablative and non-ablative laser treatments for acne scars, based on a comprehensive review of clinical trials conducted up to March 2023. The evaluation focused on clinical improvement, patient satisfaction, and the incidence of treatment-related complications. Analysis of seven studies encompassing 186 cases revealed that non-ablative lasers are more effective for atrophic acne scars, offering a better safety profile with fewer adverse effects, such as reduced pain and shorter erythema durations. Conversely, ablative laser therapy demonstrated superior results in both observer-based and patient-driven evaluations. The findings suggest that while both laser types are effective in mitigating acne scarring, the choice between ablative and non-ablative lasers should consider the balance between efficacy and safety. The study highlights the necessity for more standardized research to refine laser treatment protocols for acne scars, aiming to optimize outcomes and minimize risks.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/ddg.15651 | DOI Listing |
J Dtsch Dermatol Ges
March 2025
Department of Plastic Surgery, the First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China.
Acne scarring significantly affects physical appearance and psychological well-being, prompting the exploration of various treatment options, including ablative and non-ablative laser therapies. The debate around their efficacy and safety persists, underscoring the need for a comprehensive analysis. This meta-analysis compares the therapeutic outcomes and safety profiles of ablative and non-ablative laser treatments for acne scars, based on a comprehensive review of clinical trials conducted up to March 2023.
View Article and Find Full Text PDFFront Immunol
March 2025
Department of Immuno-Oncology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
In recent years, the rapid progress in oncology, immunology, and molecular biology has dramatically advanced cancer immunotherapy, particularly CAR-T cell therapy. This innovative approach involves engineering a patient's T cells to express receptors that specifically target tumor antigens, enhancing their ability to identify and eliminate cancer cells. However, the effectiveness of CAR-T therapy in solid tumors is often hampered by the challenging tumor microenvironment (TME).
View Article and Find Full Text PDFFront Immunol
March 2025
Rheumatology Unit, Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Turin, Italy.
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by joint pain, swelling, and stiffness, affecting approximately 1% of the adult population. Tocilizumab (TCZ), a monoclonal antibody targeting the IL-6 receptor, has emerged as an effective treatment for RA. This narrative review provides an update on TCZ's efficacy and safety based on data from randomized controlled trials (RCTs) and real-world evidence (RWE).
View Article and Find Full Text PDFFront Pharmacol
February 2025
The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.
Introduction: Modern medical treatment of insomnia is often associated with issues like addiction, drug resistance, and a high risk of relapse post drug withdrawal. To tackle these challenges, the Chinese medicine formula Shuhe granule (SHG) has been employed in insomnia treatment at Guangdong Provincial Hospital of Chinese Medicine. Despite this, there is currently a lack of reliable evidence from evidence-based trials to support the widespread use of SHG in insomnia treatment.
View Article and Find Full Text PDFFront Pharmacol
February 2025
Organon, Jersey City, NJ, United States.
Experience with the use of biosimilars in real-life practice provides an excellent opportunity to collect real-world evidence aimed at addressing residual uncertainties about biosimilars. Hence, this aims to explore the role of real-world evidence on biosimilars by showcasing how real-world evidence studies have contributed to addressing key questions affecting biosimilar market access. We find that the comparable efficacy and safety of a biosimilar and the reference product is corroborated by real-world evidence.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!